mbbirdy JMP Securities has started BeiGene ( NASDAQ: BGNE ) off at outperform citing continued growth of its lead product Brukinsa (zanubrutinib) and top-line data in 2026 from the BCL2 inhibitor sonrotoclax for chronic lymphocytic leukemia. The firm, which calls BeiGene "a unique investment opportunity," has a price.